{"id":4536,"date":"2025-03-31T18:12:11","date_gmt":"2025-03-31T18:12:11","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/interferon-alfa-2b-txt\/"},"modified":"2025-03-31T18:12:11","modified_gmt":"2025-03-31T18:12:11","slug":"interferon-alfa-2b-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/interferon-alfa-2b-txt\/","title":{"rendered":"interferon alfa 2b.txt"},"content":{"rendered":"

interferon alfa 2b <\/h1>\n

CLINICAL USE <\/H3>
\nIntron A:Chronic hepatitis B \u2014Chronic hepatitis C \u2014Hairy cell leukaemia \u2014Multiple myeloma \u2014Carcinoid tumour \u2014Chronic myelogenous leukaemia \u2014Follicular lymphoma \u2014Malignant melanoma \u2014

DOSE IN NORMAL RENAL FUNCTION <\/H3>Chronic hepatitis B: 5\u201310 million IU 3 times a weekChronic hepatitis C: 3 million IU 3 times a weekHairy cell leukaemia: 2 million IU\/m 2 3 times a weekMultiple myeloma: 3 million IU\/m 2 3 times a weekCarcinoid tumour: 3\u20139 million IU\/m 2 3 times a weekChronic myelogenous leukaemia: 4\u20135 million IU\/m2 dailyFollicular lymphoma: 5 million IU 3 times a weekMalignant melanoma: 20 million IU\/m 2 (

IV infusion <\/H4>) daily for 5 days, decreasing to 10 million IU\/m2 (SC) 3 times a week

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :15 000\u201321 000<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : Negligible<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.4<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20137

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function Monitor renal function closely
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function Monitor renal function closely
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use with great caution.

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR=10\u201320 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsImmunosuppressants, e.g. ciclosporin, tacrolimus, sirolimus may have an antagonistic effectAdministration of interferon in combination with other chemotherapeutic agents, e.g. cytarabine, cyclophosphamide, doxorubicin, teniposide may lead to increased risk of severe toxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>IM, SC, IV

    Rate of Administration <\/H4>20 minutes

    Comments<\/H4>Add to sodium chloride 0.9%

    OTHER INFORMATION <\/H4>Interferon up-regulates the cell surface presentation of class II histocompatibility antigens, which raises the possibility of drug-induced allograft rejection. There are numerous clinical reports of allograft rejection, acute renal failure and graft loss after interferon therapy. Hence extreme care should be exercised in the use of interferon after renal transplantationInterferon is metabolised primarily in the kidney. It is excreted in the urine, but is reabsorbed by the tubules where it undergoes lysosomal degradation. In patients undergoing haemodialysis, the interferon molecule may accumulate as it is too large to be dialysed and will not undergo renal degradation. Hence, the dose may need to be adjusted
    \n","protected":false},"excerpt":{"rendered":"

    interferon alfa 2b CLINICAL USE Intron A:Chronic hepatitis B \u2014Chronic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4536","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4536"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4536\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}